Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.

Helena AebersoldFabienne Foster-WitassekStefanie AeschbacherJuerg H BeerEva BlozikManuel BlumLeo BonatiGiulio ConteMichael CoslovskyMaria Luisa De PernaMarcello Di ValentinoStefan FelderCarola A HuberGiorgio MoschovitisAndreas MuellerRebecca E PaladiniTobias ReichlinNicolas RodondiAnnina StauberChristian SticherlingThomas D SzucsDavid ConenMichael KuhneStefan OsswaldMatthias SchwenkglenksMiquel Serra-Burrielnull null

Published in: Open heart (2024)

Applying a causal inference method to real-world data, we could not demonstrate switching to DOACs to be cost-effective for AF patients with at least 1 year of VKA treatment. Our estimates align with results from a previous randomised trial.

Keyphrases

end stage renal disease
atrial fibrillation
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
single cell
big data
open label
phase ii
phase iii
replacement therapy
direct oral anticoagulants
data analysis
smoking cessation